RVBA-SUNPrivate

Sun Pharma

IN
Decarbonisation trajectory · all scopes
Scope 1 + 2· base 2020 · 419k tCO2eScope 3· base 2022 · 357k tCO2e

Headline intensities

·Values in USD ($)
Peer cohort: · lower is better
Revenue intensity
Carbon / $m revenue
tCO2e / $m revenue

Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.

Operational intensity
Carbon / $m OpEx
tCO2e / $m OpEx

OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.

Economic intensity
Carbon / $m EVIC
tCO2e / $m EVIC

EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?

Asset intensity
Carbon / $m PP&E + leased
tCO2e / $m PP&E

PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.

Climate action evidence

0 records · 0 sources
Carbon credits retired
No retirement evidence on file (third-party or self-reported).
Renewable electricity
41 %
Self-reported renewable electricity share, FY2024 · 461.9 GWh
Sources
    Registry retirements are direct evidence; commitments are forward-looking pledges. EPA snapshot covers FY2019–FY2020.

    Strategy & approach

    How the firm describes its decarbonisation approach in its own words — alongside the headline numbers above. Self-reported, page-cited.

    Approach to renewable energy
    Captive hybrid (wind+solar) + rooftop solar + biomass fuel switching

    41% of energy from renewable sources in FY 2024-25, up from 31% in FY 2021-22. Strategy includes captive hybrid wind+solar plant for Gujarat facilities, captive solar at Dewas, captive windmills at Maduranthakam, expanded solar rooftop at Mohali, Poanta Sahib, Sikkim, Guwahati, Romania, Baddi sites, and fuel-substitution from furnace oil/HSD to renewable biomass briquettes for steam generation. Projecting >50% renewable energy share by 2030.

    Self-reported · FY2024 · p.59
    Approach to carbon removals
    Carbon sequestration via biodiversity/greenbelt; offset projects exploratory

    Sun Pharma is exploring carbon offset projects to neutralize residual emissions. Biodiversity assessment identified opportunities for carbon sequestration through greenbelt conservation to address residual emissions. No specific volumes of durable removals (DAC/BECCS) disclosed.

    Self-reported · FY2024 · p.70
    Primary decarbonisation levers
    • Energy efficiency in manufacturing operations

      Deployment of heat pumps for hot water (replacing steam), high-efficiency chillers with smart controls, IE3 motors, VFDs for part-load operations, energy-efficient blowers, compressors, pumps, motion-sensor lighting, and condensate recovery upgrades. Specific energy consumption reduced 7% YoY (12.68 → 11.76 GJ/Revenue Mn INR).

    • Water stewardship and ZLD

      Zero Liquid Discharge (ZLD) systems implemented at 18 manufacturing sites. 25% reduction in water consumption vs 2020 baseline; transitioning from groundwater to surface water at multiple sites; rainwater harvesting to recharge local aquifers. Target: water-positive by 2030.

    • Fuel switching from furnace oil/HSD to biomass briquettes

      Boiler fuel substitution from conventional furnace oil and high-speed diesel to renewable biomass briquettes for steam generation across most sites. This is the primary driver of Scope 1 decline from 75,970 tCO2e (FY22) to 38,729 tCO2e (FY25) — a ~49% reduction.

    Dependent decarbonisation levers
    • Purchased goods & services (Scope 3 Cat 1)

      Largest Scope 3 category. Reported 115,140 tCO2e in FY 2024-25 (down from 236,932 tCO2e in FY 2023-24). Suppliers required to abide by Supplier & Third Party Code of Conduct including ESG requirements; 64 suppliers assessed via desk-based ESG audits in FY 2024-25.

    • Upstream and downstream transportation

      Scope 3 transport categories total ~44,000 tCO2e in FY 2024-25. Mitigation includes shifting from air to sea shipments where feasible, local sourcing to reduce long-haul logistics emissions, and eco-friendly reusable multi-layered cold storage packaging for one main product to reduce CO2 emissions in distribution.

    Targets

    Near-term

    1 target
    ScopeBaseTargetReductionAlignmentProgressStatus
    Scope 1 + 2Absolute20202030−35%In corporate strategy
    14.5% reductionof −35% target · 42% there
    On track

    Net zero

    1 target
    ScopeBaseTargetReductionAlignmentProgressStatus
    Scope 1 + 22050In corporate strategyabsolute-value target

    ⚠ Some targets show progress vs the earliest extracted year as a baseline approximation. The real base-year value will be used once historical reports are extracted.

    Progress · absolute tCO2e

    Scope 1 + 2 trajectory vs target
    Scope 1 + 2 · 35% by 2030 · In corporate strategy
    ActualLinear1.5°C
    Scope 3 trajectory
    ActualLinear1.5°C

    No target available for this scope.

    Latest news· last 5 of 15

    full news log →
    • TNFD-aligned biodiversity risk assessment

      Conducted biodiversity risk assessment at 5 manufacturing locations using TNFD V0.4 framework.

      2024
    • Material reduction in Scope 3 Purchased Goods emissions

      Scope 3 Cat 1 (Purchased Goods) dropped from 236,932 to 115,140 tCO2e YoY — a 51% decrease. May reflect methodology change or scope reduction; merits verification.

      2024
    • Net Zero by 2050 commitment

      Sun Pharma set a target to become a Net Zero Company by 2050.

      2024
    • Co-process 30% of hazardous waste by 2025

      Target to co-process 30% of hazardous waste by 2025. FY 2024-25 achieved 27%.

      2024
    • 35% absolute Scope 1+2 emissions reduction target by 2030

      Sun Pharma has set a target to reduce absolute carbon emissions (Scope 1 + Scope 2) by 35% by 2030 against 2020 baseline (451,068 tCO2e). 21% reduction achieved by FY 2024-25.

      2024

    Latest reporting year· 4 earlier years on Data-by-year tab

    all years + ratios →

    2026

    reporting year
    Financials
    Revenue
    OpEx
    FTE
    Market cap (FY-end)
    Climate
    Scope 1
    Scope 2 (market)
    Scope 2 (location)
    Scope 3 total

    Source documents· FY2024

    all documents →
    sustainability report2024
    via manual upload · 9.8 MB
    extractedOPEN PDF ↗